Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model

Neurotherapeutics

Volumn 14, Issue 1, 2017, Pages 199-211

  Escribano, Begoña M ^a,b   Medina Fernández, Francisco J ^b,c   Aguilar Luque, Macarena ^b,c   Agüera, Eduardo ^b,d   Feijoo, Montserrat ^b,c   Garcia Maceira, Fe I ^e   Lillo, Rafael ^b,c   Vieyra Reyes, Patricia ^f   Giraldo, Ana I ^b,c   Luque, Evelio ^b,c   Drucker Colín, René ^g   Túnez, Isaac ^b,c,h  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Universidad de Cordoba   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e Canvax Biotech SL   (Spain)

^f UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^g INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^h Red Tematica de Investigacion Cooperativa en Envejecimiento y Fragilidad RETICEF   (Spain)

Author keywords

Dimethyl fumarate; Experimental autoimmune encephalomyelitis; Lipopolysaccharide binding protein; Natalizumab; Oxidative stress; Relapsing remitting multiple sclerosis

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; FUMARIC ACID DIMETHYL ESTER; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; NATALIZUMAB; REACTIVE OXYGEN METABOLITE; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; MALE; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPINAL CORD; ADULT; ANIMAL; BRAIN; CELL COUNT; DASYPROCTIDAE; DRUG EFFECTS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; LIPID PEROXIDATION; METABOLISM; MIDDLE AGED; NERVE CELL;

ACETYLCYSTEINE; ACUTE-PHASE PROTEINS; ADULT; ANIMALS; BRAIN; CARRIER PROTEINS; CELL COUNT; DASYPROCTIDAE; DIMETHYL FUMARATE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; NEURONS; OXIDATIVE STRESS; RATS; SPINAL CORD;

EID: 84990964630     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0480-0     Document Type: Article

References (62)

1. McQualter JL, Bernard CC. Multiple sclerosis: a battle between destruction and repair. J Neurochem 2007;100:295-306.
2. Perez-Nievas BG, Garcia-Bueno B, Madrigal JL, Leza JC. Chronic immobilisation stress ameliorates clinical score and neuroinflammation in a MOG-induced EAE in Dark Agouti rats: mechanisms implicated. J Neuroinflammation 2010;7:60.
3. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
4. Ochoa-Reparaz J, Mielcarz DW, Begum-Haque S, Kasper LH. Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. Ann Neurol 2011;69:240-247.
5. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun 2014;38:1-12.
6. Kabat EA, Wolf A, Bezer AE. Rapid production of acute disseminated encephalomyelitis in Rhesus monkeys by injection of brain tissue with adjuvants. Science 1946;104:362-363.
7. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012:148:1258-1270.
8. Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, Yamamura T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008:173:1714-1723.
9. Berer K, Mues M, Koutroulos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011:479:538-541.
10. Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: an entangled story (review). J Neuroimmune Pharmacol 2015:10:528-546.
11. Wekerle H, Berer K, Krishnamoorthy G. Remote control-triggering of brain autoimmune disease in the gut. Curr Opin Immunol 2013;25:683-689.
12. Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep2016:6:28484.
13. Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 2016:7:12015.
14. Dasgupta S, Kasper DL. Novel tools for modulating immune responses in the host-polysaccharides from the capsule of commensal bacteria. Adv Immunol 2010;106:61-91.
15. Mazmanian SK, Kasper DL. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 2006;6:849-858.
16. Riccio P. The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. Complement Ther Med 2011;19:228-237.
17. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009;15:1546-1558.
18. Guarner F. Hygiene, microbial diversity and immune regulation. Curr Opin Gastroenterol 2007;23:667-672.
19. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008;453:106-109.
20. Kim SY, Lee JG, Cho WS, et al. Role of NADPH oxidase-2 in lipopolysaccharide-induced matrix metalloproteinase expression and cell migration. Immunol Cell Biol 2010:88:197-204.
21. Bahamonde C, Conde C, Aguera E, et al. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress. Eur J Pharmacol 2014;730:26-30.
22. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 2012;314:37-40.
23. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 2012;45:26-30.
24. Tasset I, Aguera E, Gascon F, et al. Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis. Rev Neurol 2012;54:449-452.
25. Tasset I, Aguera E, Sanchez-Lopez F, et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012;45:440-444.
26. Neish AS. Redox signaling mediated by the gut microbiota. Free Radic Res 2013;47:950-957.
27. Miljkovic D, Spasojevic I. Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxidant Redox Signal 2013;19:2286-2334.
28. Stosic-Grujicic S, Ramic Z, Bumbasirevic V, Harhaji L, Mostarica-Stojkovic M. Induction of experimental autoimmune encephalomyelitis in Dark Agouti rats without adjuvant. Clin Exp Immunol 2004;136:49-55.
29. Deloire MS, Touil T, Brochet B, Dousset V, Caille JM, Petry KG. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler 2004;10:540-548.
30. Papadopoulos D, Rundle J, Patel R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010;88:346-359.
31. Kamboj SS, Sandhir R. Protective effect of N-acetylcysteine supplementation on mitochondrial oxidative stress and mitochondrial enzymes in cerebral cortex of streptozotocin-treated diabetic rats. Mitochondrion 2011;11:214-222.
32. Milenkovic M, Arsenovic-Ranin N, Vucicevic D, Bufan B, Jancic I, Stojic-Vukanic Z. Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res 2008;39:639-646.
33. Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis diagnostic criteria: three years later. Mult Scler 2005;11:5-12.
34. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
35. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478.
36. Trooster WJ, Teelken AW, Gerrits PO, et al. The effect of gonadectomy on the clinical course of chronic experimental allergic encephalomyelitis. Clin Neurol Neurosurg 1996;98:222-226.
37. Nouri M, Bredberg A, Westrom B, Lavasani S. Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. PLOS ONE 2014;9:e106335.
38. Calabrese V, Bella R, Testa D, et al. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp Clin Res 1998;24:125-131.
39. Ortiz GG, Macias-Islas MA, Pacheco-Moises FP, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Disease Markers 2009;26:35-39.
40. Ferreira B, Mendes F, Osorio N, Caseiro A, Gabriel A, Valado A. Glutathione in multiple sclerosis. Br J Biomed Sci 2013;70:75-79.
41. Wang T, Qin L, Liu B, et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 2004;88:939-947.
42. Bannerman DD, Paape MJ, Hare WR, Sohn EJ. Increased levels of LPS-binding protein in bovine blood and milk following bacterial lipopolysaccharide challenge. J Dairy Sci 2003;86:3128-3137.
43. Galea E, Reis DJ, Fox ES, Xu H, Feinstein DL. CD14 mediate endotoxin induction of nitric oxide synthase in cultured brain glial cells. J Neuroimmunol 1996;64:19-28.
44. Mancuso C, Scapagini G, Curro D, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007;12:1107-1123.
45. Usatyuk PV, Parinandi NL, Natarajan V. Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J Biol Chem 2006;281:35554-35566.
46. Breithaupt TB, Vazquez A, Baez I, Eylar EH. The suppression of T cell function and NF(kappa)B expression by serine protease inhibitors is blocked by N-acetylcysteine. Cell Immunol 1996;173:124-130.
47. Heussler VT, Fernandez PC, Machado J, Jr, Botteron C, Dobbelaere DA. N-acetylcysteine blocks apoptosis induced by N-alpha-tosyl-L-phenylalanine chloromethyl ketone in transformed T-cells. Cell Death Differ 1999;6:342-350.
48. Ljubisavljevic S, Stojanovic I, Pavlovic D, Sokolovic D, Stevanovic I. Aminoguanidine and N-acetyl-cysteine supress oxidative and nitrosative stress in EAE rat brains. Redox Rep 2011;16:166-172.
49. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-1472.
50. Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 2012;9:163.
51. Lin SX, Lisi L, Dello Russo C, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011;3.
52. Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int 2010;57:460-467.
53. Sheremata W, Brown AD, Rammohan KW. Dimethyl fumarate for treating relapsing multiple sclerosis. Exp Opin Drug Saf 2015;14:161-170.
54. Moharregh-Khiabani D, Blank A, Skripuletz T, et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLOS ONE 2010;5:e11769.
55. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-1388.
56. Radue EW, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010;292:28-35.
57. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-89.
58. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010;74(Suppl. 1):S31-S40.
59. Trebst C, Voss E, Skripuletz T, Stangel M. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. Curr Med Chem 2010;17:640-650.
60. Signoriello E, Lanzillo R, Brescia Morra V, et al. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Mult Scler 2016:22:921-925.
61. Tasset I, Bahamonde C, Aguera E, et al. Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. Pharmacol Rep 2013;65:624-631.
62. Escribano BM, Túnez I. Gut microbiota and central nervous system condemned to understand each other: their role in multiple sclerosis. MOJ Cell Sci Rep 2014;1:00005.